Changing patterns of multiple sclerosis in Korea: Toward a more baseline MRI lesions and intrathecal humoral immune responses
Hyun-June Shin(National Cancer Center), Jung‐Joon Sung(Seoul National University), Kyomin Choi(Konkuk University), Seol‐Hee Baek(Korea University Medical Center), Woojun Kim(National Cancer Center), Ohyun Kwon(Eulji University), Jong Seok Bae(Hallym University), Byung‐Jo Kim(Korea University), Eun Hee Sohn(Chungnam National University), Jung Hwan Oh(Konkuk University Medical Center), Joong‐Yang Cho(Inje University Ilsan Paik Hospital), Kee Hong Park(Hallym University), Jeeyoung Oh(Université Paris-Sud), Jae‐Won Hyun(Seoul National University Hospital), Jee‐Eun Kim(Ewha Womans University), Sung-Yeon Sohn(Seoul National University Hospital), Su‐Hyun Kim(National Cancer Center), Sung‐Min Kim(Ulsan College), Ho Jin Kim(National Cancer Center), Sun‐Young Oh(Inje University Busan Paik Hospital), Min Su Park(Yeungnam University College), Myoung‐jin Jang(Seoul National University Hospital), Byoung Joon Kim(Samsung Medical Center), Ju‐Hong Min(Samsung Medical Center)
Cited by 2
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
MOG encephalomyelitis: international recommendations on diagnosis and antibody testing
|Journal of Neuroinflammation|2018|740
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
|The Lancet|2019|722
Neuromyelitis optica
|Nature Reviews Disease Primers|2020|464
Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder
|Multiple Sclerosis Journal|2011|284